Astrazeneca PLC (AZN) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Astrazeneca PLC stock price
Astrazeneca PLC latest news:
AstraZeneca steps up China push with new drug joint venture
LONDON (Reuters) - Drugmaker AstraZeneca plans to turbo-charge its already substantial Chinese business through a new drug development joint venture with a state-backed private equity fund.
AstraZeneca ticks another box as U.S. approves severe asthma drug
* FDA clears Fasenra for patients aged 12 years and older. * AstraZeneca (AZN) prices maintenance dose below rivals. * AstraZeneca (AZN) product will vie with GSK's Nucala. By Ben Hirschler. AstraZeneca (AZN) has achieved another milestone in rebuilding its drug portfolio with U.S. approval of a drug for severe asthma as the company battles to put patent losses on older medicines behind it.
UPDATE 1-AstraZeneca ticks another box as U.S. approves severe asthma drug
* AstraZeneca product will vie with GSK's Nucala
(Adds details on pricing, competition, CEO comment)
UK Stocks-Factors to watch on Nov 15
Nov 15 (Reuters) - Britain's FTSE 100 index is seen opening down 4
points at 7,410.4 on Wednesday, according to financial bookmakers.
* ASTRAZENECA: Anglo-Swedish pharmaceutical firm AstraZeneca Plc on
Tuesday said the U.S. Food and Drug Administration approved its drug
Benralizumab, as an add-on treatment for patients with severe asthma aged 12
years and older.
* GOCMOPARE-ZPG: British company GoCompare has rejected a 460
million pound ($600 million) takeover approach made by
U.S. FDA approves AstraZeneca's asthma drug
Anglo-Swedish pharmaceutical firm AstraZeneca Plc (AZN) on Tuesday said the U.S. Food and Drug Administration approved its drug benralizumab, as an add-on treatment for patients with severe asthma aged 12 years and older. The asthma drug will be marketed under the name Fasenra in the United States. Fasenra is under regulatory review in the EU, Japan and several other countries, the company said.
BRIEF-AstraZeneca CEO still sees 2023 sales above $40 billion at today's FX
AstraZeneca CEO Pascal Soriot told reporters: * working to duplicate quality control systems so can release drugs in EU if hard Brexit. * sees high growth rate in China sustainable for next 2-3 years. * long term plan confirms we can get to $40-41 billion sales target by 2023 at current exchange rates Further company coverage:
AstraZeneca Q3 sales weak as it waits for medicine to work
AstraZeneca's(AZN) drug sales fell 3 percent in the third quarter, hit again by generic competition to former blockbusters like cholesterol pill Crestor, as it looks to new cancer treatments to revive its fortunes. Total revenue, however, rose 9 percent to $6.23 billion, helped by a $997 million payment from Merck & Co (MRK), which struck a cancer drug partnership deal with the British group in July.
BRIEF-Upsher-Smith says parent co to manufacture migraine medication in Japan With AstraZeneca
Upsher-Smith Laboratories LLC: * Upsher-Smith Laboratories says co's parent Sawai Pharmaceutical (SWPIF) entered agreement with AstraZeneca (AZN) to manufacture & market migraine medication in Japan. * Upsher-Smith Laboratories - agreement is to manufacture, market Zomig Tablets 2.5 mg & Zomig Rapid Melt Tablets 2.5 mg.
BRIEF-AstraZeneca and Merck submit application for breast cancer drug in Japan
* ASTRAZENECA AND MSD RAPIDLY ADVANCE LYNPARZA IN JAPAN
WITH A SECOND REGULATORY SUBMISSION
BRIEF-Flexion Therapeutics says co sent a notice of termination to Astrazeneca AB regarding an out-license agreement between parties
* Flexion Therapeutics Inc - on September 8, co sent a
notice of termination to Astrazeneca AB regarding an out-license
agreement between parties
Atlantic Power CorporationAT
Atlas Resource PartnersARP
Atlas Resource PartnersARP^D
Atlas Resource PartnersARP^E
Atmos Energy CorporationATO
AU Optronics CorpAUO